DRG Market Assessment 보고서

Due to the rising rates of antimicrobial resistance, antibiotics with activity against drug-resistant gram-negative pathogens are essential. Antibiotics such as carbapenems, which have historically…

The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva…

CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…

The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…

The acute lymphoblastic leukemia (ALL) therapy market is entering a dynamic period of growth driven by the introduction of targeted agents and nextgeneration cell therapies. Widely used…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 823 currently available and novel biosimilar products, detailing…

In 2024, sales of branded biologics in ophthalmology exceeded $6.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2024-2034 forecast period…

In 2024, sales of branded biologics for respiratory indications totaled $7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2024-2034 forecast…

In 2024, sales of branded biologics for endocrinology indications (insulins and antiresorptive analogues) exceeded $22 billion in the major pharmaceutical markets under study (United States, EU5,…

In 2024, sales of branded MAb biologics in neurology exceeded $12 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2024-2034 forecast period, the…

In 2024, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in the major market in…

In 2024, sales of branded MAb biologics in oncology exceeded $48 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled $5.9 billion…